{
    "clinical_study": {
        "@rank": "132690", 
        "acronym": "OBSERVA", 
        "arm_group": {
            "arm_group_label": "Asenapine", 
            "description": "Patients prescribed asenapine for any indication."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this observational study is to evaluate the use and short term safety of\n      Asenapine (Sycrest) in real-life usage in the Mental Health Trust Setting in the United\n      Kingdom(UK) National Health Service (NHS). The study is to be carried out independently by\n      the Drug Safety Research Unit (DSRU) in Southampton, although it is funded by Merck, the\n      manufacturer of Sycrest."
        }, 
        "brief_title": "Observational Post-Authorisation Safety Study of Asenapine (Sycrest)", 
        "completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Patients Prescribed Asenapine for Moderate to Severe Manic Episodes Associated With Bipolar I Disorder in Adults (or Off-label Use).", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients for whom a study questionnaire containing useful information has been\n             returned\n\n        Exclusion Criteria:\n\n          -  Patients who do not provide consent\n\n          -  Patients within selected institutions (for example prisons)\n\n          -  Patients who commenced treatment between date of market launch (to be  confirmed) and\n             study start\n\n          -  Enrolled patients for whom both the baseline and 12-week questionnaires are returned\n             blank (contain no clinical information)\n\n          -  Enrolled patients for whom the psychiatrist, designated member of clinical care team,\n             or study facilitator from the DSRU reports that the patient did not take or was never\n             prescribed asenapine\n\n          -  Enrolled patients for whom there is evidence to suggest duplication of patients\n\n          -  Enrolled patients for whom informed written or verbal notification is received by\n             DSRU indicating that they no longer wish to participate at any stage of the study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients prescribed asenapine in a NHS Mental Health Trust in England."
            }
        }, 
        "enrollment": {
            "#text": "1000", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 22, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01734278", 
            "org_study_id": "OBSERVA"
        }, 
        "intervention": {
            "arm_group_label": "Asenapine", 
            "description": "This is a non-interventional study.", 
            "intervention_name": "No intervention", 
            "intervention_type": "Other"
        }, 
        "intervention_browse": {
            "mesh_term": "Asenapine"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 8, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Stafford", 
                    "country": "United Kingdom", 
                    "state": "Staffordshire", 
                    "zip": "ST16 3SR"
                }, 
                "name": "South Staffordshire and Shropshire Healthcare NHS Foundation Trust"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_groups": "1", 
        "official_title": "An Observational Post-Authorisation Safety Specialist Cohort Monitoring Study (SCEM) to Monitor the Safety and Utilisation of Asenapine (Sycrest) in the Mental Health Trust Setting in England", 
        "overall_contact": {
            "email": "felicity.mitchell@dsru.org", 
            "last_name": "Felicity Mitchell, PhD", 
            "phone": "00442380019562"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "European Union: European Medicines Agency", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "The incidence of selected identified risks of asenapine in the mental health care trust setting", 
            "safety_issue": "Yes", 
            "time_frame": "12 weeks after asenapine is first prescribed"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01734278"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Drug Safety Research Unit, Southampton, UK", 
            "investigator_full_name": "Professor Saad Shakir", 
            "investigator_title": "Director", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "source": "Drug Safety Research Unit, Southampton, UK", 
        "sponsors": {
            "collaborator": {
                "agency": "Merck Sharp & Dohme Corp.", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Professor Saad Shakir", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "January 2013"
    }
}